StemCell Therapy

To aid our variant interpretation process, we created an openly-available online tool to efficiently classify variants based on the evidence categories outlined in the article: Richards, et al. Standards and guidelines for the interpretation of sequence variants. 2015. This site displays the evidence categories and descriptions from Table 3 and Table 4 with simple checkboxes for selecting appropriate criteria. The site then incorporates the algorithm in Table 5 to automatically assign the pathogenicity or benign impact based on the selected evidence categories. Since our process often requires analyzing multiple variants per patient, we have also allowed the option of aggregating each variant into an exportable table at the foot of the website for easy documentation of the variant review process for our records. Although this tool is based on the ACMG/AMP Standards and Guidelines, it is not affiliated with ACMG, AMP, or any of the authors of the publication.

_ PVS1 null variant (nonsense, frameshift, canonical 1 or 2 splice sites, initiation codon, single or multiexon deletion) in a gene where LOF is a known mechanism of disease

_ PS1 Same amino acid change as a previously established pathogenic variant regardless of nucleotide change _ PS2 De novo (both maternity and paternity confirmed) in a patient with the disease and no family history _ PS3 Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product _ PS4 The prevalence of the variant in affected individuals is significantly increased compared with the prevalence in controls _ PP1 (Strong evidence) Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease

_ PM1 Located in a mutational hot spot and/or critical and well-established functional domain (e.g., active site of an enzyme) without benign variation _ PM2 Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium _ PM3 For recessive disorders, detected in trans with a pathogenic variant _ PM4 Protein length changes as a result of in-frame deletions/insertions in a nonrepeat region or stop-loss variants _ PM5 Novel missense change at an amino acid residue where a different missense change determined to be pathogenic has been seen before _ PM6 Assumed de novo, but without confirmation of paternity and maternity _ PP1 (Moderate evidence) Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease

_ PP1 Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease _ PP2 Missense variant in a gene that has a low rate of benign missense variation and in which missense variants are a common mechanism of disease _ PP3 Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.) _ PP4 Patients phenotype or family history is highly specific for a disease with a single genetic etiology _ PP5 Reputable source recently reports variant as pathogenic, but the evidence is not available to the laboratory to perform an independent evaluation

_ BP1 Missense variant in a gene for which primarily truncating variants are known to cause disease _ BP2 Observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder or observed in cis with a pathogenic variant in any inheritance pattern _ BP3 In-frame deletions/insertions in a repetitive region without a known function _ BP4 Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc.) _ BP5 Variant found in a case with an alternate molecular basis for disease _ BP6 Reputable source recently reports variant as benign, but the evidence is not available to the laboratory to perform an independent evaluation _ BP7 A synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence nor the creation of a new splice site AND the nucleotide is not highly conserved

_ BS1 Allele frequency is greater than expected for disorder _ BS2 Observed in a healthy adult individual for a recessive (homozygous), dominant (heterozygous), or X-linked (hemizygous) disorder, with full penetrance expected at an early age _ BS3 Well-established in vitro or in vivo functional studies show no damaging effect on protein function or splicing _ BS4 Lack of segregation in affected members of a family

_ BA1 Allele frequency is >5% in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium

_ Sequencing artifact as determined by depth, quality, or other previously reviewed data

Download Table as CSV

Please note that the text of the variant evidence has been pulled directly from Richards, et al. Genet Med. 2015 May;17(5). This site does not claim authorship of any of the variant evidence descriptions.

This tool is based on the published ACMG/AMP Standards and Guidelines [Genet Med (2015)]. Anyone using this tool should be familiar with that publication. Individuals or institutions choosing to use this tool for clinical variant classification purposes assume legal responsibility for the consequences of its use. The authors make no warranty, express or implied, nor assume any legal liability or responsibility for any purpose for which the tool is used.

Please cite the following when using this tool in publications: Kleinberger J, Maloney KA, Pollin TI, Jeng LJ. An openly available online tool for implementing the ACMG/AMP standards and guidelines for the interpretation of sequence variants. Genet Med. 2016 Mar 17. doi: 10.1038/gim.2016.13. [Epub ahead of print] PubMed PMID: 26986878.

Read more:
Genetic Variant Interpretation Tool | University of ...

This entry was posted on June 4, 2017 at 12:48 am and is filed under Genetic medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |